Central Data Science
Together with our business and IT colleagues, we develop data science-driven solutions, all the way from ideation to product.
Search
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
US Privacy Statement
US Privacy Statement
Full data announced in DINAMO trial in young people with T2D
Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant
Oncology & Cancer Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes
Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
Ruminants
Ruminants
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
BI to Donate 75k Rabies Vaccine Doses | Boehringer Ingelheim US
Boehringer Ingelheim to donate 75,000 doses of IMRAB® vaccine to the Global Alliance for Rabies Control through shots for Good Initiative.
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
OFEV® (nintedanib) Data in Patients with ILDs | Boehringer Ingelheim US
Studies from American Thoracic Society Congress show the proportion of patients with 10% or greater declines in lung function were lower in the OFEV group.
Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US
The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.
Larry's Story: The Power of Patient Advocacy
For Larry, patient advocacy is an important part of his cancer journey. Learn more about Larry and his role with GO2 for Lung Cancer.
BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US
The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.
What can the Patient do?
What can the Patient do?
Growing fresh produce for a cause at our U.S. headquarters
Growing fresh produce for a cause at our U.S. headquarters
FDA Approves Jardiance® (empaglifozin) for T2D | BI US
Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.